A Phase II Multicenter Double-Blind Placebo-Controlled Study of Ethyl Pyruvate in High-Risk Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass

This publication has 30 references indexed in Scilit:

• Ethyl pyruvate: a novel anti‐inflammatory agent
  Journal of Internal Medicine, 2007
• Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia
  The Journal of Thoracic and Cardiovascular Surgery, 2004
• Evidence That Glutathione Depletion Is a Mechanism Responsible for the Anti-Inflammatory Effects of Ethyl Pyruvate in Cultured Lipopolysaccharide-Stimulated RAW 264.7 Cells
  The Journal of Pharmacology and Experimental Therapeutics, 2004
• Ethyl Pyruvate Provides Durable Protection Against Inflammation-Induced Intestinal Epithelial Barrier Dysfunction
  Shock, 2003
• Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion
  Intensive Care Medicine, 2003
• Ethyl Pyruvate Ameliorates Intestinal Epithelial Barrier Dysfunction in Endotoxemic Mice and Immunostimulated Caco-2 Enterocytic Monolayers
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
  Proceedings of the National Academy of Sciences, 2002
• Reactive oxygen species as mediators of organ dysfunction caused by sepsis, acute respiratory distress syndrome, or hemorrhagic shock: potential benefits of resuscitation with Ringerʼs ethyl pyruvate solution
  Current Opinion in Clinical Nutrition and Metabolic Care, 2002
• Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats
  Critical Care Medicine, 2001
• Antioxidative Properties of Pyruvate and Protection of the Ischemic Rat Heart During Cardioplegia
  Journal of Cardiovascular Pharmacology, 1999